IMMUNOPLANT for Newly Diagnosed Multiple Myeloma - Trial NCT06376526
Access comprehensive clinical trial information for NCT06376526 through Pure Global AI's free database. This Phase 2 trial is sponsored by Dickran Kazandjian, MD and is currently Not yet recruiting. The study focuses on Multiple Myeloma. Target enrollment is 28 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Dickran Kazandjian, MD
University of Miami
Timeline & Enrollment
Phase 2
Jun 30, 2024
Jun 30, 2029
Primary Outcome
Minimal Residual Disease (MRD) Negativity Rate
Summary
The purpose of this study is to determine whether Linvoseltamab therapy in patients with
 newly diagnosed multiple myeloma will convert the disease status from minimal residual
 disease (MRD)-positive to MRD-negative, and increase the length of time that the disease is
 controlled. The researchers also want to find out the effects (good and bad) that
 Linvoseltamab has on participants and the condition.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06376526
Non-Device Trial